Compare Raymond James Financial, Inc. (RJF) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs Zoetis Inc — how do they compare? Raymond James Financial, Inc. trades at $175.81 (market cap $33.75B), while Zoetis Inc trades at $73.65 (market cap $30.29B). The key difference: Raymond James Financial, Inc. and Zoetis Inc are close in size by market cap, and Zoetis Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| RJF | ZTS | |
|---|---|---|
Market Cap | $33.75B | $30.29B |
Sector | Financials | Health |
52-Week High | $181.18 | $150.61 |
52-Week Low | $140.89 | $71.91 |
Dividend Yield | 1.23% | 2.89% |
Enterprise Value | — | $37.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $176.55, down 0.98% on the day, with a mixed technical picture showing bearish overall signals but bullish moving averages. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $3.14 beating estimates of $2.93, and revenue growth from $10.9B in 2022 to $13.84B in 2025. Recent developments include dividend declarations and PGA TOUR sponsorship announcements.
RJF presents a balanced investment case with 44% analyst buy ratings and a $184.11 consensus price target offering 4.3% upside. Strengths include consistent earnings growth and wealth management expansion, while risks involve rising expenses and capital market volatility. The stock trades at reasonable valuations with P/E of 15.39 and P/S of 2.36, supported by 15.37% net margins.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
